IC50 values (as seen in Table 1) found for acarbose
which is a phenolic compound and has a positive effect were found as: Serotonin hydrochloride (0.92 uM, r2: 0.9730) < 2,4,6-Trihydroxybenzaldehyde (1.84 uM, r2: 0.9823) < 3,4-Dihydroxy-5-methoxybenzoic acid (9.63 uM, r2: 0.9773) < Acarbose
KEYWORDS: Elderly diabetics, Insulin Glargine, Acarbose
The intestinal alpha-glucosidase inhibitor acarbose
(Glucobay; Bayer, Leverkusen, Germany) hampers the digestion of carbohydrates, lowers postprandial hyperglycemia and, secondarily, hyperinsulinemia, whereas the risk of hypoglycemia is low.
The reference standard acarbose
(100 ug/ml) showed [alpha]-amylase inhibition (68.91 +- 3.09% with IC50 value of 52.99 +- 4.88 ug/ml).
Meanwhile, the partnerships Uni-Bio Science have formed with CR Zizhu (on the distribution of GeneSoftA(r) in China) and Beijing Baiao Pharmaceutical (on the development of Acarbose
under the multi-drug co-development agreement signed with Beijing Sun-Novo) have borne fruit.
Both groups received an equal amount of the drug acarbose
to help control blood glucose.
In laboratory studies, the researchers found that small concentrations of acarbose
, a drug used to treat diabetes, significantly disrupted the activity of a group of proteins involved in the Starch Utilization System (Sus).
The medication market has different pharmaceutical products of [alpha]-glucosidase inhibitors, such as acarbose
that inhibits [alpha]-amylase and [alpha]-glucosidase enzymes (7), miglitol and voglibose that inhibit [alpha]-glucosidase only (8-10).
As a classical [alpha]-glucosidase inhibitor, acarbose
lowers postprandial blood glucose levels by delaying glucose absorption, as it inhibits the enzyme that cleaves oligosaccharides into mono- and disaccharides in the intestinal lumen .
Recently, a vast number of research studies have been carried out to find potential natural antidiabetic agents since currently used drugs such as acarbose
result in noticeable gastrointestinal side effects and toxicity [7, 8].
The currently available [alpha]-glucosidase inhibitors include acarbose
(AB), voglibose (VB), and miglitol (MT).
Sample treatments include a-glucosidase inhibitors (AGIs; acarbose
, miglitol and voglibose) to reduce the absorption of carbohydrates in the intestine and control postprandial hyperglycemia.